NARCOMS Registry: A Multiple Sclerosis Registry
NARCOMS
NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis
1 other identifier
observational
50,000
1 country
1
Brief Summary
This project is based on the idea that we can learn about the complexities of MS by following disease and treatment patterns in a large group of people over several years. The information gathered is used for research only. Results are presented in summary form only. All details submitted by registry participants is strictly confidential. To participate in NARCOMS complete the baseline enrollment survey online through www.narcoms.org (or directly using the following link: https://redcap.link/py2rnyyn) or you can request a mail-in survey be sent to you by emailing MSregistry@narcoms.org. You will be asked to update your information, online or by mail, twice a year. Each update survey typically takes less than 20 minutes to complete. There is no cost to participate. For your participation you are offered a free subscription to the NARCOMS quarterly magazine, NARCOMS Now. NARCOMS Now provides a reliable source of information about the latest in MS research and disease management. You can stop participating in the registry at any time. You may also receive additional surveys or information on clinical trials. You are not obligated to participate and these additional studies will always come directly from NARCOMS. Your contact information will not be shared or sold to other parties.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1996
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1996
CompletedFirst Submitted
Initial submission to the registry
November 19, 2009
CompletedFirst Posted
Study publicly available on registry
November 23, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2050
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2050
November 13, 2025
November 1, 2025
55 years
November 19, 2009
November 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Disease progression over time of follow up
Disease Progression measured using the Patient Determined Disease Steps
up to 15 years
Secondary Outcomes (1)
Contributing factors to change in MS disease status
up to 15 years
Other Outcomes (1)
Medication usage in multiple sclerosis
up to 15 years
Eligibility Criteria
Individuals who have been diagnosed with multiple sclerosis
You may qualify if:
- Any individual who has been diagnosed with multiple sclerosis or clinically isolated syndrome
- Must be at least 18 years of age
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UT Southwestern Medical Center
Dallas, Texas, 75390-8806, United States
Related Publications (46)
Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010 Apr;183(4):1432-7. doi: 10.1016/j.juro.2009.12.029. Epub 2010 Feb 20.
PMID: 20171697BACKGROUNDBuchanan RJ, Chakravorty BJ, Tyry T, Hatcher W, Vollmer T. Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristics. NeuroRehabilitation. 2009;25(4):271-8. doi: 10.3233/NRE-2009-0525.
PMID: 20037220BACKGROUNDMarrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009 Oct 27;73(17):1394-8. doi: 10.1212/WNL.0b013e3181beece8.
PMID: 19858462BACKGROUNDHadjimichael O, Vollmer T, Oleen-Burkey M; North American Research Committee on Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008 Nov 14;6:100. doi: 10.1186/1477-7525-6-100.
PMID: 19014588BACKGROUNDMarrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Smoking status over two years in patients with multiple sclerosis. Neuroepidemiology. 2009;32(1):72-9. doi: 10.1159/000170910. Epub 2008 Nov 12.
PMID: 19001800BACKGROUNDMarrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009 Jan;15(1):105-13. doi: 10.1177/1352458508096680. Epub 2008 Oct 9.
PMID: 18845651BACKGROUNDMarrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008 Sep;14(8):1091-8. doi: 10.1177/1352458508092263.
PMID: 18728060BACKGROUNDJulian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol. 2008 Sep;255(9):1354-60. doi: 10.1007/s00415-008-0910-y. Epub 2008 Jul 17.
PMID: 18677639BACKGROUNDMarrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007 Jun 5;68(23):1971-8. doi: 10.1212/01.wnl.0000264416.53077.8b.
PMID: 17548546BACKGROUNDMarrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler. 2007 Jul;13(6):770-5. doi: 10.1177/1352458506075031. Epub 2007 Mar 15.
PMID: 17525097BACKGROUNDHadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007 Jan;127(1-2):35-41. doi: 10.1016/j.pain.2006.07.015. Epub 2006 Sep 1.
PMID: 16949751BACKGROUNDKobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006 Jun 13;66(11):1696-702. doi: 10.1212/01.wnl.0000218309.01322.5c.
PMID: 16769943BACKGROUNDMarrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006 Apr 25;66(8):1235-40. doi: 10.1212/01.wnl.0000208505.81912.82.
PMID: 16636241BACKGROUNDMarrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. 2005 Oct 11;65(7):1066-70. doi: 10.1212/01.wnl.0000178891.20579.64.
PMID: 16217060BACKGROUNDMarrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: fatigue assessment. Mult Scler. 2005 Oct;11(5):583-4. doi: 10.1191/1352458505ms1216oa.
PMID: 16193897BACKGROUNDMarrie RA, Cutter G, Tyry T, Hadjimichael O, Vollmer T. Validation of the NARCOMS Registry: pain assessment. Mult Scler. 2005 Jun;11(3):338-42. doi: 10.1191/1352458505ms1167oa.
PMID: 15957517BACKGROUNDLo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler. 2005 Feb;11(1):33-40. doi: 10.1191/1352458505ms1136oa.
PMID: 15732264BACKGROUNDRizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 Oct;10(5):589-95. doi: 10.1191/1352458504ms1085oa.
PMID: 15471378BACKGROUNDMarrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler. 2003 Oct;9(5):461-6. doi: 10.1191/1352458503ms953oa.
PMID: 14582770BACKGROUNDBuchanan RJ, Radin D, Chakravorty BJ, Tyry T. Informal care giving to more disabled people with multiple sclerosis. Disabil Rehabil. 2009;31(15):1244-56. doi: 10.1080/09638280802532779.
PMID: 19802928BACKGROUNDBuchanan R, Radin D, Chakravorty BJ, Tyry T. Perceptions of informal care givers: health and support services provided to people with multiple sclerosis. Disabil Rehabil. 2010;32(6):500-10. doi: 10.3109/09638280903171485.
PMID: 19852704BACKGROUNDFinlayson M, Cho C. A descriptive profile of caregivers of older adults with MS and the assistance they provide. Disabil Rehabil. 2008;30(24):1848-57. doi: 10.1080/09638280701707324.
PMID: 18608376BACKGROUNDFraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs. 2003 Jun;35(3):163-70. doi: 10.1097/01376517-200306000-00006.
PMID: 12830664BACKGROUNDFraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs. 2004 Jun;36(3):120-9. doi: 10.1097/01376517-200406000-00002.
PMID: 15233411BACKGROUNDMarrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 Jan 13;72(2):117-24. doi: 10.1212/01.wnl.0000333252.78173.5f. Epub 2008 Oct 29.
PMID: 18971448BACKGROUNDMarrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 Mar 30;74(13):1041-7. doi: 10.1212/WNL.0b013e3181d6b125.
PMID: 20350978BACKGROUNDBuchanan RJ, Minden SL, Chakravorty BJ, Hatcher W, Tyry T, Vollmer T. A pilot study of young adults with multiple sclerosis: demographic, disease, treatment, and psychosocial characteristics. Disabil Health J. 2010 Oct;3(4):262-70. doi: 10.1016/j.dhjo.2009.09.003. Epub 2009 Nov 26.
PMID: 21122795BACKGROUNDMarrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 Aug;124(2):135-41. doi: 10.1111/j.1600-0404.2010.01436.x. Epub 2010 Sep 29.
PMID: 20880264BACKGROUNDSalter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 2010 Feb;26(2):493-500. doi: 10.1185/03007990903500649.
PMID: 20014979BACKGROUNDBuchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, Huang C, Vollmer T. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis. 2010 Autumn;20(4):451-7.
PMID: 21305836BACKGROUNDMarrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012 Mar;125(3):180-6. doi: 10.1111/j.1600-0404.2011.01526.x. Epub 2011 May 26.
PMID: 21615355BACKGROUNDMarrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases. Neuroepidemiology. 2011;36(2):85-90. doi: 10.1159/000323948. Epub 2011 Feb 1.
PMID: 21282965BACKGROUNDCutter GR, Zimmerman J, Salter AR, Knappertz V, Suarez G, Waterbor J, Howard VJ, Marrie RA. Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord. 2015 Sep;4(5):484-490. doi: 10.1016/j.msard.2015.07.008. Epub 2015 Jul 18.
PMID: 26346799BACKGROUNDBethoux F, Marrie RA. A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis. Patient. 2016 Dec;9(6):537-546. doi: 10.1007/s40271-016-0173-0.
PMID: 27154536BACKGROUNDWang G, Marrie RA, Salter AR, Fox R, Cofield SS, Tyry T, Cutter GR. Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology. 2016 Jul 26;87(4):365-74. doi: 10.1212/WNL.0000000000002887. Epub 2016 Jun 29.
PMID: 27358338BACKGROUNDSalter A, Tyry T, Wang G, Fox RJ, Cutter G, Marrie RA. Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurol Clin Pract. 2016 Oct;6(5):397-408. doi: 10.1212/CPJ.0000000000000269.
PMID: 27847682BACKGROUNDSalter A, Thomas N, Tyry T, Cutter G, Marrie RA. Employment and absenteeism in working-age persons with multiple sclerosis. J Med Econ. 2017 May;20(5):493-502. doi: 10.1080/13696998.2016.1277229. Epub 2017 Jan 25.
PMID: 28035846BACKGROUNDReider N, Salter AR, Cutter GR, Tyry T, Marrie RA. Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis. Res Nurs Health. 2017 Apr;40(2):143-152. doi: 10.1002/nur.21783. Epub 2017 Feb 6.
PMID: 28165143BACKGROUNDMarrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ. High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology. 2017 Apr 18;88(16):1528-1534. doi: 10.1212/WNL.0000000000003831. Epub 2017 Mar 15.
PMID: 28298551BACKGROUNDMarrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A. Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. Mult Scler Relat Disord. 2017 Apr;13:87-92. doi: 10.1016/j.msard.2017.02.013. Epub 2017 Feb 20.
PMID: 28427709BACKGROUNDSalter A, Thomas NP, Tyry T, Cutter GR, Marrie RA. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. Mult Scler. 2018 Jun;24(7):951-962. doi: 10.1177/1352458517711274. Epub 2017 May 19.
PMID: 28524746BACKGROUNDMarrie RA, Sharma M, Cutter GR, Fox RJ, Salter A. Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing. Neurology. 2025 May 13;104(9):e213587. doi: 10.1212/WNL.0000000000213587. Epub 2025 Apr 8.
PMID: 40198867BACKGROUNDSalter A, Lancia S, Sharma M, Cutter GR, Fox RJ, Marrie RA. Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis. Neurol Clin Pract. 2025 Aug;15(4):e200493. doi: 10.1212/CPJ.0000000000200493. Epub 2025 Jun 4.
PMID: 40510870BACKGROUNDSalter A, Lancia S, Cutter GR, Fox RJ, Marrie RA. Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis. Neurology. 2025 Jan 28;104(2):e210149. doi: 10.1212/WNL.0000000000210149. Epub 2024 Dec 23.
PMID: 39715473BACKGROUNDO'Mahony J, Salter A, Ciftci-Kavaklioglu B, Fox RJ, Cutter GR, Marrie RA. Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis. Neurology. 2022 Oct 3;99(14):e1538-e1548. doi: 10.1212/WNL.0000000000200931.
PMID: 35948450BACKGROUNDMarrie RA, Cutter GR, Fox RJ, Vollmer T, Tyry T, Salter A. NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights. Int J MS Care. 2021 Nov-Dec;23(6):276-284. doi: 10.7224/1537-2073.2020-133. Epub 2021 Dec 29.
PMID: 35035299BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Robert J. Fox, M.D.
Mellen Center for MS / Cleveland Clinic
- PRINCIPAL INVESTIGATOR
Amber Salter, Ph.D.
University of Texas Southwestern Medical Center
- STUDY DIRECTOR
Gary R Cutter, Ph.D.
University of Alabama at Birmingham
- STUDY DIRECTOR
Ruth Ann Marrie, M.D., Ph.D.
Dalhousie University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
November 19, 2009
First Posted
November 23, 2009
Study Start
January 1, 1996
Primary Completion (Estimated)
December 1, 2050
Study Completion (Estimated)
December 1, 2050
Last Updated
November 13, 2025
Record last verified: 2025-11